324 related articles for article (PubMed ID: 30173328)
1. The relationship between quality of life, cognition, and thyroid status in Graves' disease.
Riguetto CM; Neto AM; Tambascia MA; Zantut-Wittmann DE
Endocrine; 2019 Jan; 63(1):87-93. PubMed ID: 30173328
[TBL] [Abstract][Full Text] [Related]
2. Assessing quality of life in Australian patients with Graves' ophthalmopathy.
Park JJ; Sullivan TJ; Mortimer RH; Wagenaar M; Perry-Keene DA
Br J Ophthalmol; 2004 Jan; 88(1):75-8. PubMed ID: 14693779
[TBL] [Abstract][Full Text] [Related]
3. Related quality of life questionnaire specific to dysthyroid ophthalmopathy evaluated in a population of patients with Graves' disease.
Delfino LC; Zunino A; Sapia V; Croome MDCS; Ilera V; Gauna AT
Arch Endocrinol Metab; 2017; 61(4):374-381. PubMed ID: 28225858
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the National Eye Institute visual function questionnaire in Graves' ophthalmopathy.
Bradley EA; Sloan JA; Novotny PJ; Garrity JA; Woog JJ; West SK
Ophthalmology; 2006 Aug; 113(8):1450-4. PubMed ID: 16769116
[TBL] [Abstract][Full Text] [Related]
5. Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey.
Törring O; Watt T; Sjölin G; Byström K; Abraham-Nordling M; Calissendorff J; Cramon PK; Filipsson Nyström H; Hallengren B; Holmberg M; Khamisi S; Lantz M; Wallin G
Thyroid; 2019 Mar; 29(3):322-331. PubMed ID: 30667296
[TBL] [Abstract][Full Text] [Related]
6. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
[TBL] [Abstract][Full Text] [Related]
7. Chronology of Graves' ophthalmopathy in an incidence cohort.
Bartley GB; Fatourechi V; Kadrmas EF; Jacobsen SJ; Ilstrup DM; Garrity JA; Gorman CA
Am J Ophthalmol; 1996 Apr; 121(4):426-34. PubMed ID: 8604736
[TBL] [Abstract][Full Text] [Related]
8. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
[TBL] [Abstract][Full Text] [Related]
9. Studies on the occurrence of ophthalmopathy in Graves' disease.
Marcocci C; Bartalena L; Bogazzi F; Panicucci M; Pinchera A
Acta Endocrinol (Copenh); 1989 Apr; 120(4):473-8. PubMed ID: 2718699
[TBL] [Abstract][Full Text] [Related]
10. Assessment of quality of life and depression in Korean patients with Graves' ophthalmopathy.
Lee H; Roh HS; Yoon JS; Lee SY
Korean J Ophthalmol; 2010 Apr; 24(2):65-72. PubMed ID: 20379454
[TBL] [Abstract][Full Text] [Related]
11. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
[TBL] [Abstract][Full Text] [Related]
12. IGF1 deficiency in newly diagnosed Graves' disease patients.
Martin S; Sirbu A; Betivoiu M; Florea S; Barbu C; Fica S
Hormones (Athens); 2015; 14(4):651-9. PubMed ID: 26188228
[TBL] [Abstract][Full Text] [Related]
13. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study.
Marcocci C; Bruno-Bossio G; Manetti L; Tanda ML; Miccoli P; Iacconi P; Bartolomei MP; Nardi M; Pinchera A; Bartalena L
Clin Endocrinol (Oxf); 1999 Oct; 51(4):503-8. PubMed ID: 10583319
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of quality of life in patients with Graves orbitopathy and its influencing factors].
Weng CY; Li ZF; Hu SD; Luo YS; Feng XT; Zhong Q; Zhang Q; Shen J
Zhonghua Nei Ke Za Zhi; 2019 Aug; 58(8):577-583. PubMed ID: 31365979
[No Abstract] [Full Text] [Related]
15. Psychiatric manifestations of Graves' hyperthyroidism: pathophysiology and treatment options.
Bunevicius R; Prange AJ
CNS Drugs; 2006; 20(11):897-909. PubMed ID: 17044727
[TBL] [Abstract][Full Text] [Related]
16. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
[TBL] [Abstract][Full Text] [Related]
17. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.
Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR
J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210
[TBL] [Abstract][Full Text] [Related]
18. Quality of life assessment in patients with Graves' disease and progressive infiltrative ophthalmopathy during combined treatment with methylprednisolone and orbital radiotherapy.
Kulig G; Andrysiak-Mamos E; Sowińska-Przepiera E; Kulig J; Karakiewicz B; Brodowski J; Robaczyk M; Homa K; Letkiewicz M; Syrenicz A
Endokrynol Pol; 2009; 60(3):158-65. PubMed ID: 19569015
[TBL] [Abstract][Full Text] [Related]
19. Treating the thyroid in the presence of Graves' ophthalmopathy.
Hegedüs L; Bonnema SJ; Smith TJ; Brix TH
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):313-24. PubMed ID: 22632368
[TBL] [Abstract][Full Text] [Related]
20. Quality of life in Graves' ophthalmopathy.
Wiersinga WM
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):359-70. PubMed ID: 22632371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
